[Following curative resection of colorectal cancer, portal chemotherapy especially benefits non-transfused patients]
- PMID: 2112083
[Following curative resection of colorectal cancer, portal chemotherapy especially benefits non-transfused patients]
Abstract
After curative resection of colorectal cancer, immediate short-term postoperative intraportal adjuvant chemotherapy reduces the relative risk of recurrence and death in the non-transfused patient significantly, when compared to transfused patients without chemotherapy. This is demonstrated in a multivariate analysis using the Cox model on a group of 469 patients who have been intraoperatively randomized to receive either intraportal chemotherapy for 7 days or no further treatment. The transfused patients with chemotherapy and those receiving neither transfusions nor chemotherapy had a relative risk of recurrence and death situated in between the two groups mentioned above, not statistically different from either of them. In the setting of this study, 7 days postoperative intraportal chemotherapy seems particularly effective in the non-transfused patients.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical